美托洛尔对心力衰竭大鼠心肌MMP-2&9的影响(4)
[7] SHEN X C, QIAN Z Y. Matrix metalloproteinases-A new target of the treatment of cardiac hypertrophy[J]. Phamacutical Biotechnol,2003,10(5):325-328.
[8] TIYYAGURA S R, PINNEY S P. Left ventricular remodeling after myocardial infarction: past, present, and future[J]. Mt Sinai J Med,2006,73(6):840-851.
[9] TAKENAKA H, KIHARA Y, IWANAGA Y, et al. Angiotensin Ⅱ, oxidative stress, and extracellular matrix degradation during transition to LV failure in rats with hypertension[J]. J Mol Cell Cardiol,2006,41(6):989- 997.
[10] BANFI C, CAVALCA V, VEGLIA F, et al. Neurohormonal activation is associated with increased levels of plasma matrix metalloproteinase-2 in human heart failure[J]. Eur Heart J,2005,26(5):481-488.
[11] SPINALE F G, GUNASINGHE H, SPRUNGER P D, et al. Extracellular degradative pathways in myocardial remodeling and progression to heart failure[J]. J Card Fail,2002,8(6S):S332-S338.
[12] NAGATOMO Y, YOSHIKAWA T, KOHNO T, et al. A pilot study on the role of autoantibody targeting the beta1-adrenergic receptor in the response to beta-blocker therapy for congestive heart failure[J].J Card Fail,2009,15(3):224-232.
[13] WUERZNER G, CHIOLERO A, MAILLARD M, et al. Metoprolol prevents sodium retention induced by lower body negative pressure in healthy men[J]. Kidney Int,2005,68(2):688-694.
[14] FIORDALISO F, de ANGELIS N, BAI A, et al. Effect of beta-adrenergic and renin-angiotensin system blockade on myocyte apoptosis and oxidative stress in diabetic hypertensive rats[J]. Life Sci,2007,81(12): 951- 959., 百拇医药(郭 寒 陆 乐 赵智明 郭郡浩 赵凌杰 蔡 辉)
[8] TIYYAGURA S R, PINNEY S P. Left ventricular remodeling after myocardial infarction: past, present, and future[J]. Mt Sinai J Med,2006,73(6):840-851.
[9] TAKENAKA H, KIHARA Y, IWANAGA Y, et al. Angiotensin Ⅱ, oxidative stress, and extracellular matrix degradation during transition to LV failure in rats with hypertension[J]. J Mol Cell Cardiol,2006,41(6):989- 997.
[10] BANFI C, CAVALCA V, VEGLIA F, et al. Neurohormonal activation is associated with increased levels of plasma matrix metalloproteinase-2 in human heart failure[J]. Eur Heart J,2005,26(5):481-488.
[11] SPINALE F G, GUNASINGHE H, SPRUNGER P D, et al. Extracellular degradative pathways in myocardial remodeling and progression to heart failure[J]. J Card Fail,2002,8(6S):S332-S338.
[12] NAGATOMO Y, YOSHIKAWA T, KOHNO T, et al. A pilot study on the role of autoantibody targeting the beta1-adrenergic receptor in the response to beta-blocker therapy for congestive heart failure[J].J Card Fail,2009,15(3):224-232.
[13] WUERZNER G, CHIOLERO A, MAILLARD M, et al. Metoprolol prevents sodium retention induced by lower body negative pressure in healthy men[J]. Kidney Int,2005,68(2):688-694.
[14] FIORDALISO F, de ANGELIS N, BAI A, et al. Effect of beta-adrenergic and renin-angiotensin system blockade on myocyte apoptosis and oxidative stress in diabetic hypertensive rats[J]. Life Sci,2007,81(12): 951- 959., 百拇医药(郭 寒 陆 乐 赵智明 郭郡浩 赵凌杰 蔡 辉)